{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:00:59Z","timestamp":1789063259710,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.clinthera.2021.10.003","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T18:25:43Z","timestamp":1634149543000},"page":"2046-2063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Utility of Remote Inspections During the COVID-19 Health Emergency and in the Postpandemic Setting"],"prefix":"10.1016","volume":"43","author":[{"given":"Sarah","family":"Mofid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winona Rei","family":"Bolislis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Brading","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Hardit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Parain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4149-3545","authenticated-orcid":false,"given":"Thomas C.","family":"K\u00fchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clinthera.2021.10.003_bib0001","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clinthera.2020.11.015","article-title":"Regulatory agilities in the time of COVID-19: Overview, Trends and Opportunities","volume":"43","author":"Bolislis","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2021.10.003_bib0002","unstructured":"EUDRAGMPD. http:\/\/eudragmdp.ema.europa.eu\/inspections\/gmpc\/searchGMPCompliance.do?ctrl=searchGMPCResultControlList&action=Drilldown&param=8642."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0003","unstructured":"MHRA. New arrangements for MHRA Good Practice (GxP) inspections due to coronavirus (COVID-19). March 2020. https:\/\/www.gov.uk\/government\/news\/new-arrangements-for-mhra-good-practice-gxp-inspections-due-to-coronavirus-covid-19\u20132."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0004","unstructured":"EMA. Questions and answers on regulatory expectations for medicinal products. 2020. https:\/\/ec.europa.eu\/health\/sites\/health\/files\/human-use\/docs\/guidance_regulatory_covid19_en.pdf."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0005","unstructured":"European Medicine Agency. Guidance on remote GCP inspections during the COVID19 pandemic. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guidance-remote-gcp-inspections-during-covid-19-pandemic_en.pdf."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0006","unstructured":"European Medicine Agency. Guidance related to GMP\/GDP and PMF distant assessment. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guidance-related-gmp\/gdp-pmf-distant-assessments_en.pdf."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0007","unstructured":"European Medicine Agency. Remote pharmacovigilance inspections of MAHs during a crisis situation: points to consider. 2012. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/remote-pharmacovigilance-inspections-mahs-during-crisis-situation-points-consider_en.pdf."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0008","unstructured":"FDA, Manufacturing, Supply Chain, and Drug Inspections | COVID-19. January 29, 2021. https:\/\/www.fda.gov\/drugs\/coronavirus-covid-19-drugs\/manufacturing-supply-chain-and-drug-inspections-covid-19."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0009","unstructured":"FDA. Manufacturing, Supply Chain, and Drug and Biological Product Inspections During COVID-19 Public Health Emergency Questions and Answers Guidance for Industry. 2020-2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/manufacturing-supply-chain-and-drug-and-biological-product-inspections-during-covid-19-public-health."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0010","unstructured":"Therapeutic Good Administration. TGA expectations for overseas manufacturing sites hosting remote inspections during the COVID-19 pandemic. 2020. https:\/\/www.tga.gov.au\/tga-expectations-overseas-manufacturing-sites-hosting-remote-inspections-during-covid-19-pandemic."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0011","unstructured":"Therapeutic Good Administration. GMP approach to overseas manufacturers of medicines and biologicals during the COVID-19 pandemic. 2020. https:\/\/www.tga.gov.au\/gmp-approach-overseas-manufacturers-medicines-and-biologicals-during-covid-19-pandemic."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0012","unstructured":"PMDA. Procedure for Remote Inspection as a part of compliance inspection on drugs and regenerative medical products. 2020. https:\/\/www.pmda.go.jp\/files\/000238733.pdf."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0013","unstructured":"PMDA. https:\/\/www.pmda.go.jp\/files\/000235011.pdf."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0014","unstructured":"Jerry Chapman Redica, \u00abRussian Inspectorate Weighs in on Remote Audits and International Harmonization. https:\/\/redica.com\/pharma-russian-inspectorate-weighs-in-on-remote-audits-and-international-harmonization\/."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0015","unstructured":"EUDRAGMPD. Certificate of GMP Compliance of a Manufacturer issued by French Health Authority ANSM. 2009. http:\/\/eudragmdp.ema.europa.eu\/inspections\/gmpc\/searchGMPCompliance.do."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0016","unstructured":"EMA. Notice to stakeholders: questions and answers on regulatory expectations for medicinal products for human use during the COVID-19 pandemic. 2020. https:\/\/www.ema.europa.eu\/en\/news\/guidance-regulatory-requirements-context-covid-19-pandemic."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0017","unstructured":"FDA. Regenerative Medicine Advanced Therapy Designation,\u00bb https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/regenerative-medicine-advanced-therapy-designation#:\u223c:text=As%20described%20in%20Section%203033,therapy%20(RMAT)%20designation%20if%3A&text=Preliminary%20clinical%20evidence%20ind."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0018","unstructured":"FDA. What does FDA inspect? 2018. https:\/\/www.fda.gov\/about-fda\/fda-basics\/what-does-fda-inspect."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0019","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1208\/s12248-012-9415-9","article-title":"Common Reasons for \u201cFor-Cause\u201d Inspections in Bioequivalence Studies Submitted to the Food and Drug Administration","volume":"15","author":"Li","year":"2013","journal-title":"AAPS J"},{"key":"10.1016\/j.clinthera.2021.10.003_bib0020","unstructured":"FDA. Guidance for Industry on Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection. 2014. https:\/\/www.fda.gov\/media\/86328\/download"},{"key":"10.1016\/j.clinthera.2021.10.003_bib0021","unstructured":"FDA voices, Woodcock and McMeeking. FDA's Ongoing Use of Inspectional Tools for Ensuring Access to Safe, Quality Food and Medical Products During the COVID-19 Pandemic. 2021. https:\/\/www.fda.gov\/news-events\/fda-voices\/fdas-ongoing-use-inspectional-tools-ensuring-access-safe-quality-food-and-medical-products-during."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0022","unstructured":"FDA. Coronavirus (COVID-19) Update: FDA prepares for resumption of domestic inspections with new risk assessment system. July 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-prepares-resumption-domestic-inspections-new-risk-assessment-system."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0023","unstructured":"GAO report, United States Government Accountability Office Report to Congressional Committees. COVID-19 Critical Vaccine Distribution, Supply Chain, Program Integrity, and Other Challenges Require Focused Federal Attention. January 2021. https:\/\/www.gao.gov\/products\/gao-21-265"},{"key":"10.1016\/j.clinthera.2021.10.003_bib0024","unstructured":"FDAnews\u2019 15th Annual Inspections Summit. Keynote Address: The FDA Perspective on Inspections: What's Happening Now and What to Expect in 2021. November 2019. Key address presented at: 15th Annual FDA Inspections vSummit; November 17\u201318, 2020."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0025","unstructured":"FDA. Extension and Expansion of Temporary extraordinary measures related to MDSAP audits during covid-19 quarantine orders and travel restrictions \u2013 Remote audits. 2020. https:\/\/www.fda.gov\/media\/136441\/download"},{"key":"10.1016\/j.clinthera.2021.10.003_bib0026","unstructured":"IMDRF. http:\/\/www.imdrf.org\/."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0027","unstructured":"FDA. Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency. April 14, 2021. https:\/\/www.fda.gov\/media\/147582\/download."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0028","unstructured":"FDA, Janet Woodcock, M.D.. FDA Provides Guidance on Remote Interactive Evaluations for Oversight of Drug Facilities During COVID-19. April 14, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-provides-guidance-remote-interactive-evaluations-oversight-drug-facilities-during-covid-19."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0029","unstructured":"FDA. Resiliency Roadmap for FDA Inspectional Oversight. May 2021. https:\/\/www.fda.gov\/media\/148197\/download?utm_medium=email&utm_source=govdelivery."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0030","unstructured":"M. Medicines and Healthcare products Regulatory Agency, \u00abNew arrangements for MHRA Good Practice (GxP) inspections due to coronavirus (COVID-19),\u00bb 2020."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0031","unstructured":"Medicines and Healthcare products Regulatory Agency. Guidance for industry on MHRA's expectations for return to UK on-site inspection. https:\/\/www.gov.uk\/guidance\/guidance-for-industry-on-mhras-expectations-for-return-to-uk-on-site-inspections"},{"key":"10.1016\/j.clinthera.2021.10.003_bib0032","unstructured":"David Churchward, MHRA inspectorate. MHRA Good Practice (GxP) inspections during the COVID19 outbreak. 2020. https:\/\/mhrainspectorate.blog.gov.uk\/2020\/03\/23\/mhra-good-practice-gxp-inspections-during-the-covid19-outbreak\/."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0033","unstructured":"David Churchward, MHRA UK Inspectorate Blog. MHRA Good Practice (GxP) inspections during the COVID19 outbreak. 2020. https:\/\/mhrainspectorate.blog.gov.uk\/2020\/03\/23\/mhra-good-practice-gxp-inspections-during-the-covid19-outbreak\/"},{"key":"10.1016\/j.clinthera.2021.10.003_bib0034","unstructured":"GMP clearance for overseas manufacturers, https:\/\/www.tga.gov.au\/book\/export\/html\/5338."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0035","unstructured":"WHO. Regulating medicine manufacturers: is an on-site inspection the only option? The Australian approach to meeting inspection demands. 2017. https:\/\/apps.who.int\/iris\/handle\/10665\/330963."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0036","unstructured":"Pharmaceutical Inspection Co-Operation Scheme Annual Report. 2019. https:\/\/picscheme.org\/docview\/3486."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0037","unstructured":"EudraGMDP Database, 15 July 2020. http:\/\/eudragmdp.ema.europa.eu\/inspections\/gmpc\/searchGMPCompliance.do?ctrl=searchGMPCResultControlList&action=Drilldown&param=96442."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0038","unstructured":"FDA inspection dashboard. https:\/\/datadashboard.fda.gov\/ora\/cd\/inspections.htm."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0039","unstructured":"FDA. FDA inspection classification database. https:\/\/www.accessdata.fda.gov\/scripts\/inspsearch\/."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0040","unstructured":"ORA, FDA. Remarks at the Food and Drug Law Institute Annual Conference. https:\/\/www.fda.gov\/news-events\/speeches-fda-officials\/remarks-food-and-drug-law-institute-annual-conference-10062020."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0041","unstructured":"FDA. FDA Form 483 Frequently Asked Questions. September 2020. https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/inspection-references\/fda-form-483-frequently-asked-questions."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0042","unstructured":"FDA. Inspection Observations. https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/inspection-references\/inspection-observations."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0043","unstructured":"ICMRA. ICMRA aims for international alignment on policy approaches and regulatory flexibility during COVID-19 pandemic. April 2020. http:\/\/www.icmra.info\/drupal\/news\/21April2020."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0044","unstructured":"PIC\/S. New PIC\/S guidance on GMP inspection reliance based on draft by ICMRA with aim to maximise inspection resources for GMP compliance of overseas facilities. 2017. https:\/\/picscheme.org\/en\/news\/new-pic-s-guidance-on-gmp-inspection-reliance-based-on-draft-by-icmra-with-aim-to-maximise-inspection-resources-for-gmp-compliance-of-overseas-facilities-."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0045","unstructured":"PIC\/S. GMP Inspection Reliance. 2018. https:\/\/picscheme.org\/users_uploads\/news_news_documents\/PI_048_1_Guidance_on_GMP_Inspection_Reliance_1.pdf."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0046","unstructured":"FDA, Janet Woodcock. Safeguarding Pharmaceutical Supply Chains in a Global Economy. 2019. https:\/\/www.fda.gov\/news-events\/congressional-testimony\/safeguarding-pharmaceutical-supply-chains-global-economy-10302019."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0047","unstructured":"Devon E. McMahon, Gregory A. Peters et Louise C. Global resource shortages during COVID-19: Bad news for low-income countries. https:\/\/journals.plos.org\/plosntds\/article?id=10.1371\/journal.pntd.0008412"},{"key":"10.1016\/j.clinthera.2021.10.003_bib0048","unstructured":"European Commission. Proposal for a Regulation of the European Parliament and of the Council on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices. 2020. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A52020PC0725"},{"key":"10.1016\/j.clinthera.2021.10.003_bib0049","unstructured":"Paula Walker, MHRA GCP Inspectorate Operations Manager and Senior GCP inspector. Inspectors grounded - a year of innovation. March 26, 2021. https:\/\/mhrainspectorate.blog.gov.uk\/2021\/03\/26\/inspectors-grounded-a-year-of-innovation\/."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0050","unstructured":"Benedicte Lebreton, Genentech's head of CMC regulatory for biologics development. CASSS WCBP workshop - Digital Technologies as a Key Enabler to Meet the Current and Future. February 2021. https:\/\/pink.pharmaintelligence.informa.com\/PS143821\/How-Genentech-Pivoted-To-Digital-During-The-Pandemic."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0051","unstructured":"Richard L. Friedman, Associate Director, Office of Manufacturing and Product Quality Office of Compliance Center for Drug Evaluation and Research FDA, Current Expectations for Pharmaceutical Quality Systems. 2012. https:\/\/www.fda.gov\/media\/84744\/download"},{"key":"10.1016\/j.clinthera.2021.10.003_bib0052","unstructured":"Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to strengthen and modernize agency's oversight and reporting of inspections for sterile injectable drugs. 2018. https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-fda-commissioner-scott-gottlieb-md-new-steps-strengthen-and-modernize-agencys-oversight."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0053","unstructured":"RAPS. Regulators discuss expectations and challenges in conducting virtual inspections. 2021. https:\/\/www.raps.org\/news-and-articles\/news-articles\/2021\/4\/regulators-discusses-expectations-and-challenges-i?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%2029%20April%202021."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0054","unstructured":"Hayes. 2020 ISPE Europe Annual Conference. 2020. https:\/\/ispe.org\/pharmaceutical-engineering\/ispeak\/regulators-hpra-hsa-mhra-tga-discuss-distant-assessments."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0055","unstructured":"Australian Government - Department of the Prime Minister and Cabinet, International Standards and Risk Assessments. December 14, 2014. https:\/\/www.pmc.gov.au\/resource-centre\/regulation\/international-standards-and-risk-assessments."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0056","unstructured":"EMA. Mutual recognition agreements (MRA). https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/compliance\/good-manufacturing-practice\/mutual-recognition-agreements-mra#united-states-section."},{"key":"10.1016\/j.clinthera.2021.10.003_bib0057","doi-asserted-by":"crossref","unstructured":"T. Dombrowski and Mielke U. 2013. Lean Leadership \u2013 Fundamental Principles and their Application. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S221282711300303X","DOI":"10.1016\/j.procir.2013.06.034"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821003982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821003982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:55:35Z","timestamp":1758963335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821003982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":57,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0149291821003982"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.10.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Utility of Remote Inspections During the COVID-19 Health Emergency and in the Postpandemic Setting","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}